Top

Published in:

Open Access 01-04-2017 | Lung Cancer (HA Wakelee, Section Editor)

A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer

Authors: Tresa McGranahan, MD PhD, Seema Nagpal, MD

Published in: Current Treatment Options in Oncology | Issue 4/2017

Opinion statement

Management of non-small cell lung cancer (NSCLC) with brain metastasis (BrM) has been revolutionized by identification of molecular subsets that have targetable oncogenes. Historically, survival for NSCLC with symptomatic BrM was weeks to months. Now, many patients are surviving years with limited data to guide treatment decisions. Tumors with activating mutations in epidermal growth factor receptor (EGFRact+) have a higher incidence of BrM, but a longer overall survival. The high response rate of both systemic and BrM EGFRact+ NSCLC to tyrosine kinase inhibitors (TKIs) has led to the rapid incorporation of new therapies but is outpacing evidence-based decisions for BrM in NSCLC. While whole brain radiation therapy (WBRT) was the foundation of management of BrM, extended survival raises concerns for the subacute and late effects radiotherapy. We favor the use of TKIs and delaying the use of WBRT when able. At inevitable disease progression, we consider alternative dosing schedules to increase CNS penetration (such as pulse dosing of erlotinib) or advance to next generation TKI if available. We utilize local control options of surgery or stereotactic radiosurgery (SRS) for symptomatic accessible lesions based on size and edema. At progression despite available TKIs, we use pemetrexed-based platinum doublet chemotherapy or immunotherapy if the tumor has high expression of PDL-1. We reserve the use of WBRT for patients with more than 10 BrM and progression despite TKI and conventional chemotherapy, if performance status is appropriate.

•• Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol. 2016; doi:10.1001/jamaoncol.2016.3834. Updated prognositc scale for BrM in lung cancer accounting for mutational status.PubMed

• Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med. 2015;139(4):469–80. doi:10.5858/arpa.2014-0128-RA. Review of mutations in lung adenocardinoma.PubMedCrossRef

Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. N Engl J Med. 2016;374(19):1864–73. doi:10.1056/NEJMra1504688.PubMedCrossRef

Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest. 1984;74(2):647–51. doi:10.1172/jci111463.PubMedPubMedCentralCrossRef

Di Carlo A, Mariano A, Coppa A, Macchia V, Maiuri F, Iaconetta G, et al. Epidermal growth factor receptor and tissue tumor markers in human intracranial neoplasms. J Neurosurg Sci. 1990;34(3–4):181–5.PubMed

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39. doi:10.1056/NEJMoa040938.PubMedCrossRef

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500. doi:10.1126/science.1099314.PubMedCrossRef

• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911. EGFRact+ worldwide incidence with maps for mutation frequency as well as reported ranges based on gender and smoking status.PubMedPubMedCentral

Hughes AN, O’Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol. 2009;27(8):1220–6. doi:10.1200/JCO.2008.19.3995.PubMedPubMedCentralCrossRef

10.

Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-Oncology. 2010;12(11):1193–9. doi:10.1093/neuonc/noq076.PubMedPubMedCentralCrossRef

11.

Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624–31. doi:10.1183/09031936.00195609.PubMedCrossRef

12.

• Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139–62. doi:10.1016/j.ctrv.2016.03.009. Systematic review of quality of life and survival in patients with NSCLC.PubMedCrossRef

13.

Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118(2):257–62. doi:10.1002/ijc.21496.PubMedCrossRef

14.

Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi:10.1126/scitranslmed.3002003.PubMedPubMedCentralCrossRef

15.

Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005;103(11):2344–8. doi:10.1002/cncr.21033.PubMedCrossRef

16.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18(16):4406–14. doi:10.1158/1078-0432.CCR-12-0357.PubMedPubMedCentralCrossRef

17.

Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget. 2015;6(10):8366–76. doi:10.18632/oncotarget.3187.PubMedPubMedCentralCrossRef

18.

Fang L, Sun X, Song Y, Zhang Y, Li F, Xu Y, et al. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study. Cancer Chemother Pharmacol. 2015;76(4):873–7. doi:10.1007/s00280-015-2847-z.PubMedCrossRef

19.

Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15(7):1042–7. doi:10.1093/annonc/mdh276.PubMedCrossRef

20.

Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, et al. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer. 2012;48(3):377–84. doi:10.1016/j.ejca.2011.10.016.PubMedCrossRef

21.

Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, et al. Gefitinib in patients with brain metastases from non–small-cell lung cancer: review of 15 clinical cases. Clinical Lung Cancer. 2004;6(2):123–8. doi:10.3816/CLC.2004.n.026.PubMedCrossRef

22.

Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib in a Chinese population. Lung Cancer. 2009;65(2):198–203. doi:10.1016/j.lungcan.2008.10.028.PubMedCrossRef

23.

•• Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82(2):282–7. doi:10.1016/j.lungcan.2013.08.016. Trial design of advancing from gefitinib to erlotinib prior to salvage XRT that resulted in delayed XRT 17.9m.PubMedCrossRef

24.

Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65(3):351–4. doi:10.1016/j.lungcan.2008.12.011.PubMedCrossRef

25.

• Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, et al. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Thorac Cancer. 2016;7(6):648–54. doi:10.1111/1759-7714.12379. Retrospective study of upfront TKI and salvage radiotherapy.PubMedPubMedCentralCrossRef

26.

Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, et al. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Med Oncol. 2016;33(8):97. doi:10.1007/s12032-016-0811-3.PubMedPubMedCentralCrossRef

27.

Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010;5(7):950–5. doi:10.1097/JTO.0b013e3181e2138b.PubMedCrossRef

28.

Deng Y, Feng W, Wu J, Chen Z, Tang Y, Zhang H, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2(1):116–20. doi:10.3892/mco.2013.190.PubMed

29.

Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011;6(7):1287–9. doi:10.1097/JTO.0b013e318219ab87.PubMedCrossRef

30.

Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P, Xu Y. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer. 2010;70(2):174–9. doi:10.1016/j.lungcan.2010.01.018.PubMedCrossRef

31.

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011;30(4):419–25. doi:10.1200/jco.2011.38.0527.PubMedPubMedCentralCrossRef

32.

Lind JS, Lagerwaard FJ, Smit EF, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1391–6. doi:10.1016/j.ijrobp.2008.10.026.PubMedCrossRef

33.

• Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N, et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst. 2014;106(7) doi:10.1093/jnci/dju151. Prospective trial with no survival benefit to combination of eroltinib and WBRT in EGFRwt patients.

34.

Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31(7):895–902. doi:10.1200/JCO.2011.40.1174.PubMedPubMedCentralCrossRef

35.

Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90):90ra59. doi:10.1126/scitranslmed.3002356.PubMedPubMedCentralCrossRef

36.

Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology. 2011;13(12):1364–9. doi:10.1093/neuonc/nor121.PubMedPubMedCentralCrossRef

37.

• Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran B, Cross J, et al. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol. 2016; doi:10.1093/annonc/mdw556. Phase I pulse dosing of erlotinib with BrM response and no CNS progression.

38.

Zhou L, He J, Xiong W, Liu Y, Xiang J, Yu Q, et al. Impact of whole brain radiation therapy on CSF penetration ability of icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: results of phase I dose-escalation study. Lung Cancer. 2016;96:93–100. doi:10.1016/j.lungcan.2016.04.003.PubMedCrossRef

39.

Fan Y, Huang Z, Fang L, Miao L, Gong L, Yu H, et al. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer. Cancer Chemother Pharmacol. 2015;76(3):517–23. doi:10.1007/s00280-015-2760-5.PubMedCrossRef

40.

Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016; doi:10.1093/annonc/mdw322.

41.

Schuler M, Wu YL, Hirsh V, O’Byrne K, Yamamoto N, Mok T, et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11(3):380–90. doi:10.1016/j.jtho.2015.11.014.PubMedCrossRef

42.

Hochmair M, Holzer S, Burghuber OC. Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases. Anti-Cancer Drugs. 2016;27(9):914–5. doi:10.1097/CAD.0000000000000410.PubMedCrossRef

43.

Kashima J, Okuma Y, Miwa M, Hosomi Y. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors. Med Oncol. 2016;33(11):129. doi:10.1007/s12032-016-0843-8.PubMedCrossRef

44.

Zheng MH, Sun HT, Xu JG, Yang G, Huo LM, Zhang P, et al. Combining whole-brain radiotherapy with gefitinib/erlotinib for brain metastases from non-small-cell lung cancer: a meta-analysis. Biomed Res Int. 2016;2016:5807346. doi:10.1155/2016/5807346.PubMedPubMedCentral

45.

Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556–60. doi:10.1016/j.lungcan.2012.05.092.PubMedCrossRef

46.

Park K, Tan E-H, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–89. doi:10.1016/s1470-2045(16)30033-x.PubMedCrossRef

47.

Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013;31(27):3335–41. doi:10.1200/JCO.2012.45.0981.PubMedCrossRef

48.

Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009;4(11):1415–9. doi:10.1097/JTO.0b013e3181b62572.PubMedCrossRef

49.

Nonagase Y, Okamoto K, Iwasa T, Yoshida T, Tanaka K, Takeda M, et al. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report. Anti-Cancer Drugs. 2016;27(3):251–3. doi:10.1097/CAD.0000000000000317.PubMedCrossRef

50.

Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schutz M, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156–63. doi:10.1097/JTO.0000000000000380.PubMedCrossRef

51.

Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer. 2013;119(24):4325–32. doi:10.1002/cncr.28364.PubMedCrossRef

52.

Ohara S, Ushijima T, Gunji M, Tanai C, Tanaka Y, Noda H, et al. Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report. J Med Case Rep. 2014;8:64. doi:10.1186/1752-1947-8-64.PubMedPubMedCentralCrossRef

53.

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2016; doi:10.1056/NEJMoa1612674. Randomized trial with benefit in PFS for osimertinib compared to conventional chemotherapy in EGFRact+ patients 30% of had asymptomtic BrM.PubMed

54.

Reichegger H, Jochum W, Forbs D, Hader C, Fruh M. Rapid intracranial response to osimertinib in a patient with epidermal growth factor receptor T790M-positive adenocarcinoma of the lung. Oncol Res Treat. 2016;39(7–8):461–3. doi:10.1159/000446759.PubMedCrossRef

55.

Ricciuti B, Chiari R, Chiarini P, Crino L, Maiettini D, Ludovini V, et al. Osimertinib (AZD9291) and CNS response in two radiotherapy-naive patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer. Clin Drug Investig. 2016;36(8):683–6. doi:10.1007/s40261-016-0411-1.PubMedCrossRef

56.

Yang J, Kim DW, Kim SW, Cho BC, Lee J, Ye X, et al., editors. Osimertinib activity in patients with leptomeningeal disease from non-small cell lung cancer: updated results from the BLOOM study. Chicago, IL: ASCO Annual Meeting 2015; 2016.

57.

• Tan CS, Cho BC, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer. 2016;93:59–68. doi:10.1016/j.lungcan.2016.01.003. Review of currently available and pipline TKIs.PubMedCrossRef

58.

Ahn MJ, Kim DW, Kim TM, Lin C, Ratnayake J, Carlile DJ, et al., editors. Phase I study (BLOOM) of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). Chicago, IL: ASCO Annual Meeting 2016; 2016.

59.

Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, et al. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol. 2007;59(4):461–6. doi:10.1007/s00280-006-0285-7.PubMedCrossRef

60.

Dinglin XX, Huang Y, Liu H, Zeng YD, Hou X, Chen LK. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. J Neuro-Oncol. 2013;112(3):461–6. doi:10.1007/s11060-013-1079-5.CrossRef

61.

Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22(11):2466–70. doi:10.1093/annonc/mdr003.PubMedCrossRef

62.

Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg M, et al. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer. 2012;13(1):24–30. doi:10.1016/j.cllc.2011.05.007.PubMedCrossRef

63.

Zhu W, Roe OD, Wu C, Li W, Guo R, Gu Y, et al. Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study. J Chemother. 2015;27(4):221–6. doi:10.1179/1973947815Y.0000000005.PubMedCrossRef

64.

Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–902. doi:10.1200/JCO.2012.47.1102.PubMedCrossRef

65.

Soria JC, Wu Y-L, Nakagawa K, Kim S-W, Yang J-J, Ahn M-J, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990–8. doi:10.1016/s1470-2045(15)00121-7.PubMedCrossRef

66.

Schvartsman G, Ferrarotto R, Massarelli E. Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol. 2016;8(6):460–73. doi:10.1177/1758834016661164.PubMedPubMedCentralCrossRef

67.

Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355–63. doi:10.1158/2159-8290.CD-13-0310.PubMedCrossRef

68.

•• Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–83. doi:10.1016/S1470-2045(16)30053-5. Open label phase 2 of use of checkpoint inhibitor, pembrolizumab in NSCLC with brain metastasis.PubMedCrossRef

69.

Kanai O, Fujita K, Okamura M, Nakatani K, Mio T. Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases. Ann Oncol. 2016; doi:10.1093/annonc/mdw148.

70.

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):20–30. doi:10.1093/annonc/mds590.PubMedCrossRef

71.

• Besse B, Le Moulec S, Mazieres J, Senellart H, Barlesi F, Chouaid C, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015;21(8):1896–903. doi:10.1158/1078-0432.CCR-14-2082. Phase II study of use of BEV in patients with untreated non-squamous NSCLC BrM.PubMedCrossRef

72.

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–44. doi:10.1016/s1470-2045(14)70381-x.PubMedCrossRef

73.

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500. doi:10.1056/nejm199002223220802.PubMedCrossRef

74.

Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33(6):583–90. doi:10.1002/ana.410330605.PubMedCrossRef

75.

Kim SY, Hong CK, Kim TH, Hong JB, Park CH, Chang YS, et al. Efficacy of surgical treatment for brain metastasis in patients with non-small cell lung cancer. Yonsei Med J. 2015;56(1):103–11. doi:10.3349/ymj.2015.56.1.103.PubMedCrossRef

76.

Barker 2nd FG. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100(5):999–1007. doi:10.1002/cncr.20058.PubMedCrossRef

77.

•• Lim SH, Lee JY, Lee MY, Kim HS, Lee J, Sun JM, et al. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Ann Oncol. 2015;26(4):762–8. doi:10.1093/annonc/mdu584. PhaseIII trial examining upfront SRS to conventional chemotherapy. Study was closed early due to approval of TKIs as first line, but did not show a benefit to early SRS.PubMedCrossRef

78.

•• Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys. 2016;95(2):673–9. doi:10.1016/j.ijrobp.2016.01.037. Retrospective study with survival benefit to upfront SRS with TKI compared to salvage SRS.PubMedCrossRef

79.

Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.PubMedCrossRef

80.

Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12(1):59–67.PubMedCrossRef

81.

Cai L, Zhu J-f, Zhang X-w, Lin S-x, Su X-d, Lin P, et al. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neuro-Oncol. 2014;120(2):423–30. doi:10.1007/s11060-014-1570-7.CrossRef

82.

Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiation therapy oncology group 0320. Int J Radiat Oncol Biol Phys. 2013;85(5):1312–8. doi:10.1016/j.ijrobp.2012.11.042.PubMedPubMedCentralCrossRef

83.

• Soon YY, Leong CN, Koh WY, Tham IW. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol. 2015;114(2):167–72. doi:10.1016/j.radonc.2014.12.011. Meta-analysis suggesting benefit to upfront radiotherapy compared to salvage stratedy.PubMedCrossRef

84.

•• Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al., editors. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016; doi:10.1016/s0140-6736(16)30825-x. No benefit to WBRT compared to steroids and best supportive care in patients who were not canidates for other local therapy. Study period largely pre-dated use of TKIs.

85.

Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res. 2008;14(1):162–8. doi:10.1158/1078-0432.ccr-07-1468.PubMedCrossRef

86.

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387–95. doi:10.1016/s1470-2045(14)70061-0.PubMedCrossRef

87.

Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg. 2006;104(6):907–12. doi:10.3171/jns.2006.104.6.907.PubMedCrossRef

88.

Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72. doi:10.1016/s0140-6736(04)16250-8.PubMedCrossRef

89.

Rades D, Huttenlocher S, Hornung D, Blanck O, Schild SE. Radiosurgery alone versus radiosurgery plus whole-brain irradiation for very few cerebral metastases from lung cancer. BMC Cancer. 2014;14:931. doi:10.1186/1471-2407-14-931.PubMedPubMedCentralCrossRef

90.

Bowden G, Kano H, Caparosa E, Park S-H, Niranjan A, Flickinger J, et al. Gamma knife radiosurgery for the management of cerebral metastases from non–small cell lung cancer. J Neurosurg. 2015;122(4):766–72. doi:10.3171/2014.12.jns141111.PubMedCrossRef

91.

Churilla TM, Handorf E, Soffietti R, Kocher M, Aizer AA, Collette L, et al. Does whole-brain radiation therapy for oligometastatic brain metastases translate into a survival benefit for patients with a limited competing risk from extracranial disease? A secondary analysis of EORTC 22952-26001. Int J Radiat Oncol Biol Phys. 96(2):S56–S7. doi:10.1016/j.ijrobp.2016.06.147.

92.

Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44. doi:10.1016/s1470-2045(09)70263-3.PubMedCrossRef

93.

Zhuang H, Wang J, Zhao L, Yuan Z, Wang P. The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int J Cancer. 2013;133(10):2277–83. doi:10.1002/ijc.28290.PubMedCrossRef

94.

Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65(8):3328–35. doi:10.1158/0008-5472.can-04-3547.PubMed

95.

Liu Y, Deng L, Zhou X, Zhou L, Xu Y, Gong Y, et al. Early radiation therapy combined with EGFR-TKI is associated with longer survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys. 2016;96(2):E436. doi:10.1016/j.ijrobp.2016.06.1725.CrossRef

96.

Magnuson WJ, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, et al. Deferring radiation therapy for brain metastases in patients with EGFR-mutant non-small cell lung cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2016;96(2S):S57–S8. doi:10.1016/j.ijrobp.2016.06.149.CrossRef

97.

Stokes TB, Niranjan A, Kano H, Choi PA, Kondziolka D, Dade Lunsford L, et al. White matter changes in breast cancer brain metastases patients who undergo radiosurgery alone compared to whole brain radiation therapy plus radiosurgery. J Neuro-Oncol. 2015;121(3):583–90. doi:10.1007/s11060-014-1670-4.CrossRef

98.

•• Cohen-Inbar O, Melmer P, Lee CC, Xu Z, Schlesinger D, Sheehan JP. Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery. J Neuro-Oncol. 2016;126(2):289–98. doi:10.1007/s11060-015-1962-3. Study looking at rates of leukoencephalopathy in long term survivors for both SRS alone and SRS with history of WBRT.CrossRef

99.

Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487–95. doi:10.1016/j.ijrobp.2009.12.061.PubMedPubMedCentralCrossRef

100.

Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology. 2013;15(10):1429–37. doi:10.1093/neuonc/not114.PubMedPubMedCentralCrossRef

101.

Marsh JC, Gielda BT, Herskovic AM, Abrams RA. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: current concepts and approaches. J Oncol. 2010;2010:198208. doi:10.1155/2010/198208.PubMedPubMedCentralCrossRef

102.

Gondi V, Hermann BP, Mehta MP, Tome WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(2):348–54. doi:10.1016/j.ijrobp.2012.11.031.PubMedCrossRef

103.

Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2013;24(4):993–9. doi:10.1093/annonc/mds529.PubMedCrossRef

104.

Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther. 2013;7:1179–86. doi:10.2147/DDDT.S53011.PubMedPubMedCentralCrossRef

105.

Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007;57(3):359–64. doi:10.1016/j.lungcan.2007.03.011.PubMedCrossRef

106.

Zeng Y-D, Zhang L, Liao H, Liang Y, Xu F, Liu J-L, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac J Cancer Prev. 2012;13(3):909–14. doi:10.7314/apjcp.2012.13.3.909.PubMedCrossRef

107.

Ge H, Zhu Q, Sun Y. Comparing the clinical efficacy of TKI alone with TKI plus concomitant WBRT for EGFR mutation-positive lung adenocarcinoma patients with brain metastases: a retrospective study. Int J Radiat Oncol Biol Phys. 2016;96(2S):S132. doi:10.1016/j.ijrobp.2016.06.322.CrossRef

Title: A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
Authors: Tresa McGranahan, MD PhD
Seema Nagpal, MD
Publication date: 01-04-2017
Publisher: Springer US
Published in: Current Treatment Options in Oncology / Issue 4/2017
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-017-0466-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 4/2017

Optimal Radiation Therapy for Small Cell Lung Cancer

The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment

Image-Guided Thermal Ablative Therapies in the Treatment of Sarcoma

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease

Keynote webinar | Spotlight on antibody–drug conjugates in cancer